The Top 5 Biosimilars Articles for the Week of January 14

January 18, 2019

The Center for Biosimilars® recaps the top news for the week of January 14, 2019.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 14.

Number 5: A recently published study found that shifting reimbursement of some Medicare Part B drugs to Medicare Part D could increase out-of-pocket spending for some Medicare beneficiaries.

Number 4: Two studies published earlier this month found that biosimilar infliximab, CT-P13, had positive safety and efficacy data when switching patients with inflammatory bowel disease to the biosimilar.

Number 3: The House Committee on Oversight and Reform has launched a wide-ranging investigation into prescription drug pricing in the United States.

Number 2: In an interview with The Center for Biosimilars®, partners at Goodwin explained the impact that biosimilar developers will feel from the ongoing government shutdown.

Number 1: A representative from Pfizer has confirmed to The Center for Biosimilars® that the company has terminated 5 of its preclinical biosimilar programs after the results of the company’s annual investment review.

Finally, last week, our e-newsletter asked if the current administration is doing enough to curb cost growth for pharmaceuticals.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Regulatory | Business | Policy

x